Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,013 public trials 2,032 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

NCT01743989

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +17 more
Locations
  • Novartis Investigative Site Linz, Upper Austria, Austria
  • Novartis Investigative Site Graz, Austria
  • Novartis Investigative Site Linz, Austria
  • Novartis Investigative Site Linz, Austria
View all 208 locations
View Trial Details
Completed

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

NCT02676778

Conditions
Cutaneous T-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Eisai Trial Site #1 Nagoya, Aichi-ken, Japan
  • Eisai Trial Site #2 Nagoya, Aichi-ken, Japan
  • Eisai Trial Site #1 Kashiwa, Chiba, Japan
  • Eisai Trial Site #1 Ōta, Gunma, Japan
View all 20 locations
View Trial Details
Completed

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

NCT02432235

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +9 more
Locations
  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center) Duarte, California, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
  • University Hospitals Cleveland Medical Center Cleveland, Ohio, United States
  • The University of Texas/MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

NCT03993288

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Sandoz Investigative Site Krasnogorsk, Russia
  • Sandoz Investigative Site Moscow, Russia
  • Sandoz Investigative Site Saint Petersburg, Russia
  • Sandoz Investigative Site Saint Petersburg, Russia
View all 18 locations
View Trial Details
Completed

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

NCT02283775

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number 840001 Scottsdale, Arizona, United States
  • Investigational Site Number 840006 Duarte, California, United States
  • Investigational Site Number 840018 New Haven, Connecticut, United States
  • Investigational Site Number 840011 Decatur, Illinois, United States
View all 13 locations
View Trial Details
Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

NCT02933320

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • Leicester Royal Infirmary Leicester, England, United Kingdom
  • Christie Hospital Manchester, England, United Kingdom
  • Oxford Cancer and Haematology Centre, Churchill Hospital Oxford, England, United Kingdom
  • Derriford Hospital Plymouth, United Kingdom
View Trial Details

Related conditions